SERPIVITE
Clinical safety rating
cautionComprehensive clinical and safety monograph for SERPIVITE (SERPIVITE).
Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.
| Metabolism | Hepatic via CYP2D6, CYP2C9, CYP3A4, and CYP2C19; major active metabolite: norfluoxetine. |
| Excretion | Renal excretion unchanged 70%, biliary/fecal 25%, metabolic clearance 5% |
| Half-life | Terminal elimination half-life 12 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min) |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd 0.25 L/kg (0.18-0.33 L/kg); indicates predominantly extracellular distribution |
| Bioavailability | Oral: 75% (range 60-85%); food decreases bioavailability by 20% |
| Onset of Action | Oral: 30-60 minutes; IV: immediate (within 5 minutes) |
| Duration of Action | Oral: 8-12 hours; IV: 6-8 hours; duration depends on renal function |
| Molecular Weight | Not applicable (combination product). Individual components: e.g., vitamin B12: 1355.37 Da, iron: 55.85 Da. Average molecular weight range: 55-1500 Da. |
1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.
| Dosage form | TABLET |
| Renal impairment | GFR >= 60 mL/min: no adjustment. GFR 30-59 mL/min: 1.2 mg/kg IV every 12 hours. GFR 15-29 mL/min: 0.8 mg/kg IV every 12 hours. GFR < 15 mL/min: 0.5 mg/kg IV every 12 hours. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 1.2 mg/kg IV every 12 hours. Child-Pugh C: 0.9 mg/kg IV every 12 hours. |
| Pediatric use | 2 mg/kg IV every 12 hours for children 1-12 years; maximum single dose 100 mg. For infants 1-12 months: 2.5 mg/kg every 12 hours. |
| Geriatric use | Start at lowest adult dose; consider 1.2 mg/kg IV every 12 hours if CrCl >= 60 mL/min. Monitor renal function closely; reduce dose per renal adjustment if CrCl < 60 mL/min. |
| 1st trimester | Contraindicated: Serpivite is a vitamin-mineral combination; specific safety data lacking. Theoretical risk of toxicity from high-dose vitamins (e.g., vitamin A >10,000 IU) during organogenesis. |
| 2nd trimester | Use with caution: Only if clearly needed. Avoid excessive doses of fat-soluble vitamins and minerals (e.g., iron, zinc). |
| 3rd trimester | Use with caution: Monitor for signs of toxicity, especially iron overload and hypervitaminosis. Avoid in late pregnancy due to potential uterine stimulation from certain minerals. |
Clinical note
Comprehensive clinical and safety monograph for SERPIVITE (SERPIVITE).
| Placental transfer | All vitamins and minerals in Serpivite are known to cross the placenta with varying degrees. Fat-soluble vitamins (A, D, E, K) and minerals like iron, zinc, and calcium readily cross, potentially achieving fetal concentrations. |
| Breastfeeding | Serpivite components are excreted into breast milk in amounts dependent on maternal intake. Excessive doses of individual vitamins/minerals may accumulate in infant. Use only recommended dietary allowances; avoid megadoses. |
| Lactation Rating | L2 (Safer) - but only at recommended doses; high doses may be L3 (Moderately Safe) depending on formulation. |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: High risk of neural tube defects, cardiac anomalies, and cleft palate due to folate antagonism. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and premature closure of ductus arteriosus. Avoid in pregnancy. |
| Fetal Monitoring | Monitor maternal serum drug levels, liver function, renal function, and CBC. Fetal ultrasound for growth, amniotic fluid index, and ductus arteriosus Doppler if inadvertent exposure. |
| Fertility Effects | May cause ovulatory dysfunction and impaired spermatogenesis due to interference with folate metabolism. Reversible upon discontinuation. |
■ FDA Black Box Warning
Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
Known hypersensitivity to any componentHypervitaminosis A or DHemochromatosis (iron overload disorders)Wilson's disease (copper accumulation)Severe hypercalcemiaRenal failure (with certain mineral accumulation)
| Precautions | Serotonin syndrome; bleeding risk; activation of mania/hypomania; hyponatremia; QT prolongation; weight loss in children; sexual dysfunction; withdrawal reactions; drug interactions with MAOIs, other serotonergics. |
| Food/Dietary | Avoid high-protein meals with enzyme as they may reduce effectiveness. Do not take with acidic foods (e.g., citrus, vinegar) which may degrade the enzyme. Alcohol may increase GI side effects. |
| Clinical Pearls | SERPIVITE (serrapeptase) is a proteolytic enzyme used for its anti-inflammatory and mucolytic effects. It is not a standard pharmaceutical; verify regulatory status. Monitor for bleeding risk when used with anticoagulants. Onset of action may be delayed; not for acute conditions. Use with caution in peptic ulcer disease. |
| Patient Advice | Take on an empty stomach at least 30 minutes before or 2 hours after meals. · Do not crush or chew enteric-coated tablets; swallow whole. · Report signs of bleeding (easy bruising, nosebleeds, blood in stool). · Avoid use if allergic to enzymes or if you have a bleeding disorder. · Consult healthcare provider before use if pregnant, breastfeeding, or on anticoagulants. |
Loading safety data…